Julian Baker’s Eikon Therapeutics EIKN Stock Holding History

Julian Baker’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.25M	Hold	555,555	–	–	0.04%	73
2026 Q1	$5.88M	Buy	+555,555	New	+$7.43M	0.03%	74

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Julian Baker's EIKN Position: Q2 2026 in Review

Julian Baker held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 555,555 shares worth $7.25M. The position accounts for 0.04% of the portfolio, ranked #73.

Julian Baker first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

Julian Baker held 555,555 shares of Eikon Therapeutics worth $7.25M as of Q2 2026.
Julian Baker left its Eikon Therapeutics share count unchanged in Q2 2026.
Eikon Therapeutics made up 0.04% of Julian Baker's portfolio in Q2 2026, its #73 holding.
Julian Baker first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
76 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.